Just as it’s illegal for you and me to print money, but perfectly legal for the government to print money, there may come a time when the government deems it necessary to analyze your DNA for reasons of “efficiency” or “cost-effectiveness.”It is truly amazing how rapidly a feat which was once hailed as one of the most difficult achievements in the history of humanity is now something that may cost as little as $1,000 in a few years.
Medical device maker Stryker Corp. said Tuesday that it reached a deal to buy privately held Surpass Medical Ltd. for $100 million in cash, plus up to $35 million in milestone payments. Stryker said the addition of Surpass expands its product lineup in the fast-growing neurovascular market, while also broadening its stroke care product offerings.
Medical device maker CareFusion Corp. said Monday it agreed to buy Intermed Equipamento Medico Hospitalar, a Brazilian respiratory technology company. CareFusion said Intermed designs, makes and sells ventilators and respiratory care devices used in hospitals in Brazil and Latin America.
With today’s 21st Century technology and the speed and accessibility of data or information from the internet, medical device manufacturers are faced with unique — and at times unprecedented — trends in meeting consumer needs as well as global regulatory requirements.
Medtronic Inc. will buy China Kanghui Holdings for $816 million, helping it expand in one of the world's fastest growing medical device markets. China Kanghui Holdings makes orthopedics devices, specializing in trauma, spine and joint reconstruction.
Scientists reported Thursday that they succeeded in creating tiny medical devices sealed in silk cocoons that did the work they were designed for, then dissolved in the bodies of lab mice. It's an early step in a technology that may hold promise, not only for medicine, but also for disposal of electronic waste.
Blood analysis systems developer Abaxis Inc. said Wednesday it will receive $17.25 million from medical test maker Cepheid Inc. as part of a patent litigation settlement. Abaxis said the litigation focused on several of its patents tied to reagent and chemical compositions and processes. All claims against Cepheid will be dismissed as part of the settlement.
One-of-a-kind industry event Medical Manufacturing Innovations (MMI Toronto) 2012, which takes place October 24-25 at the International Centre in Mississauga, has unveiled a dynamic conference line-up. Conference sessions will cover hot topics including metal injection molding, additive manufacturing applications, and advanced multi-material molding processes to help provide solutions and pertinent education to the industry.
Medical and security imaging equipment maker Analogic Corp. said Thursday its net income more than doubled in the fiscal fourth quarter on greater sales of ultrasound and security products. Analogic said its new products, a larger direct-sales force, and increased efficiency helped its results.
Covidien said Wednesday it will close the plant in Seneca over the next three years as it moves operations to Costa Rica. The plant makes elastic hospital products, medical bandages and surgical supplies. It employs about 595 full-time and temporary contract employees.
U.S. attorney's spokesman Thom Mrozek says 50-year-old David Ji of Irvine pleaded guilty Monday to charges of illegally distributing a drug that the Food and Drug Administration has not approved for distribution. The version of the drug distributed through DNP International Company, Inc., contained the human growth hormone somatropin.
Androgel is one of a growing number of prescription gels, patches and injections aimed at boosting the male hormone that begins to decline after about age 40. Drugmakers and some doctors claim testosterone therapy can reverse some of the signs of aging — even though the safety and effectiveness of such treatments is unclear.
Federal prosecutors say a medical supply company from Mississippi will pay almost $1.8 million to end fraud claims in Alabama. A settlement was filed Wednesday in Birmingham in a lawsuit involving Pinnacle Medical Solutions of Southhaven, Miss.
The Federal Trade Commission has long held that brand-name pharmaceutical companies may not pay generic-drug companies to stay out of the market. To its dismay, the FTC has had great difficulty convincing the courts that its dim view of such “reverse payments” is correct.
One clever approach to handling a particular recurring deviation was to have a pre-printed form. The investigation was already written with the exception of the slight nuances, which were accommodated by blanks. This "Mad Lib" approach was completed in a matter of minutes, and a quality assurance (QA) approval was handily secured.
Patient after patient asked: Is eating organic food, which costs more, really better for me? Unsure, Stanford University doctors dug through reams of research to find out — and concluded there's little evidence that going organic is much healthier, citing only a few differences involving pesticides and antibiotics.
Merck has suffered development and marketing setbacks including the abandonment of its multiple sclerosis drug Cladibrine after it was rejected by EU regulators and questioned by the U.S. Food and Drug Administration. The company will try to find the cuts through either not filling the posts of people who leave or workers opting to take early retirement.
The German manufacturer of anti-morning sickness drug thalidomide has for the first time apologized to people who were born with congenital birth defects as a result of its use. Chief executive Harald Stock said Friday that the company had failed to reach out "from person to person" to the victims and their mothers over the past 50 years.
Bristol-Myers Squibb Co. is recalling more than 31,000 units of a chemotherapy drug after discovering one vial was overfilled, putting patients at risk of an overdose. The company's action affects 10 lots of BiCNU, an injection of the drug carmustine, used to treat brain tumors, multiple myeloma, Hodgkin's disease and non-Hodgkin's lymphoma.
The FDA says the warning is based on cases of cataract seen in juvenile rats studied by the drug's manufacturer, Vertex Pharmaceuticals. The study was designed to show that Kalydeco is safe for children younger than 2 years old. Cataract is a clouding of the eye's lens that can disrupt vision.
The Lake Forest, Ill., company said it received the letter Thursday. The FDA said the facility was not complying with the agency's rules. The agency also said Hospira's initial response to the inspection was inadequate because the company has not made changes to correct problems, hasn't created proper procedures for accepting products coming in, and is not keeping adequate records of the devices it makes.
The company said Thursday that it was ending development of Inhibitex's most advanced drug candidate because of the death of one patient in a mid-stage clinical trial. Bristol-Myers stopped the trial on Aug. 1. It disclosed charge in a filing with the Securities and Exchange Commission Friday and said the write-down will be part of its third-quarter results.
The Food and Drug Administration is warning consumers not to use Reumofan dietary supplements, after receiving reports of bleeding, stroke and death among people taking the pills. Reumofan Plus and Reumofan Plus Premium are marketed as natural remedies for arthritis and muscle pain, but the FDA says the products actually contain several prescription drugs.
If brand-name prescription medicines cost you as little as generic pills, which would you choose? A few drugmakers are betting Americans will stick with the name they know — and can pronounce. They've begun offering U.S. patients coupons to reduce copayments on brand-name medicines getting their first generic competition to about the same as for the new generic drug.
The company will remove potentially cancer-causing and other dangerous chemicals from nearly all its adult products in the next 3 1/2 years.